Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 11Breast Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 8Carcinoma, Merkel Cell 8Neoplasms 7Colorectal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Penile Neoplasms 2Pancreatic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm, Residual 2Mesothelioma, Malignant 2

Interventions

Sunitinib 26Everolimus 20Bevacizumab 19aldesleukin 18Sorafenib 16Nivolumab 16Interleukin-2 14pembrolizumab 13Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 12Radiotherapy 12Interferon-alpha 12Cyclophosphamide 12Radiosurgery 11Filgrastim 11Blood Specimen Collection 11Ipilimumab 10Gemcitabine 10Axitinib 9Surveys and Questionnaires 7Gene Expression Profiling 7Cryosurgery 7temsirolimus 6pazopanib 6Surgical Procedures, Operative 6durvalumab 5cabozantinib 5atezolizumab 5Mycophenolic Acid 5Immunohistochemistry 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Kidney Neoplasms × avelumab × Clear all
NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡